Hi-Tech Pharmacal Co., Inc. 369 Bayview Avenue Amityville,
NY 11701 United States - Map Phone: 631-789-8228 Fax: 631-789-8429 Website: http://www.hitechpharm.com
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription and over-the-counter (OTC) products in the United States. It operates in three segments: Generic Pharmaceuticals, OTC Branded Pharmaceuticals, and Prescription Brands. The company manufactures liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic, and inhalation products. The pipeline includes sterile ophthalmic products, controlled substances, oral solutions, and suspensions and solid dosage forms. Hi-Tech Pharmacal Co. also develops and markets OTC products for the diabetes marketplace, which include Diabetic Tussin, DiabetiDerm, Multi-betic, Mag-Ox, Choice DM, and DiabetiSweet primarily for people with diabetes; capsaicin products under the Zostrix name for pain management of conditions comprising arthritis and foot pain; Nasal Ease homeopathic allergy reliever; and Sinus Buster homeopathic sinus congestion reliever. In addition, the company markets and distributes branded prescription products to treat various disease states, including tension headache, pain, contact dermatitis, wound care, sleep disorders, and swimmers ear. It serves chain drug stores, drug wholesalers, managed care purchasing organizations, federal government agencies, generic distributors, mass merchandisers, and mail order pharmacies. The company was founded in 1982 and is based in Amityville, New York. Key Statistics
| |
| Hi-Tech Pharmacal Co., Inc.’s ISS Governance QuickScore as of May 1, 2013 is 8. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 2; Compensation: 8. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. David S. Seltzer ,
53 Chairman, Chief Exec. Officer, Pres, Sec. and Treasurer | 878.00K | 3.40M | Mr. Reuben C. Seltzer ,
57 Vice Chairman, Vice Chairman of Bus. Devel. and Consultant On Legal Matters & Special Projects | 812.00K | 2.03M | Mr. William J. Peters ,
46 Chief Financial Officer and VP of Fin. | 549.00K | 0.00 | Mr. Kamel Egbaria Ph.D.,
55 Chief Scientific Officer and Exec. VP | 586.00K | 0.00 | Mr. Davis S. Caskey ,
65 VP of Pharmaceutical Operations - ECR Pharmaceuticals | 335.00K | 0.00 |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|